Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,597 across all filing types
Latest filing 2015-04-08 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
拟收购海南海力制药有限公司100%股权项目资产评估报告
Regulatory Filings
2015-04-08 Chinese
备考合并财务报表审阅报告
Regulatory Filings
2015-04-08 Chinese
海南海力制药有限公司审计报告
Regulatory Filings
2015-04-08 Chinese
关于公司股票继续停牌暨一般风险提示公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from Guangdong Taicheng Pharmaceutical Co., Ltd. regarding the continued suspension of its stock trading due to a major asset restructuring plan. It references previous announcements about the suspension and progress updates, and it warns investors about risks related to the suspension and potential insider trading investigations. The document does not contain financial statements or detailed financial data but is an update on the status of a capital market event (stock suspension and asset restructuring progress). It is not a full report like an Annual Report or Interim Report, nor is it a call transcript or earnings release. It is an announcement related to capital/financing activities, specifically about stock suspension due to a major asset restructuring. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is short (1010 characters), but it is not merely announcing the publication of a report; it provides substantive update information about the stock suspension and restructuring progress.
2015-04-08 Chinese
重大资产购买报告书（草案）摘要
Capital/Financing Update Classification · 95% confidence The document is a detailed report titled "重大资产购买报告书（草案）" which translates to "Major Asset Purchase Report (Draft)". It describes a significant asset acquisition transaction where Guangdong Taicheng Pharmaceutical Co., Ltd. plans to acquire 100% equity of Haili Pharmaceutical. The document includes transaction details, pricing, funding sources, impact on the company, risk factors, approvals, and legal and financial advisor opinions. It is a comprehensive disclosure related to a major asset purchase, which is a form of significant corporate transaction involving acquisition of assets or equity. This fits the category of Capital/Financing Update (CAP) as it relates to updates on company fundraising, financing activities, or capital structure changes. It is not an announcement of a report publication, nor a full annual or interim report, nor a merger proxy or tender offer filing. It is a detailed transaction report on a major asset purchase, consistent with CAP filings. The document length (15,000 characters) and content confirm it is a full report, not a brief announcement or certification. Therefore, the appropriate classification is CAP with high confidence.
2015-04-08 Chinese
第二届监事会第十二次会议决议公告
Capital/Financing Update Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Guangdong Taicheng Pharmaceutical Co., Ltd. It details the approval of various proposals related to a major asset purchase and a non-public issuance of A shares, including voting results and procedural compliance. The document is a formal announcement of board meeting decisions and approvals, not a full financial report or detailed presentation. It primarily concerns capital raising activities and approvals for share issuance, with no substantive financial statements or detailed analysis included. The document length is 3810 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the document fits best under the category of Capital/Financing Update (CAP), as it provides updates on company fundraising and capital structure changes through non-public share issuance and related approvals.
2015-04-08 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.